Ahmet Parlak

Ahmet Parlak

Auto-generated profile, based on publicly available information

Ahmet Parlak

İ.E. Ulagay İlaç Sanayii Türk A.Ş.

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 September 2022 in Fabad Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
FYFırat Yerli̇kaya
Fırat Yerli̇kaya
AAAslihan ARSLAN
Aslihan ARSLAN
ÖAÖzlem Ati̇k
Özlem Ati̇k
SKSeda Kozan
Seda Kozan
APAhmet Parlak
Ahmet Parlak
SAS. Peri Aytac
S. Peri Aytac
A new oral formulation of cefdinir, Cefdinir 600 mg Tablets has been developed and in this study, its relative bioavailability has been compared with another oral solid dosage form, Cefdinir 300 mg Capsules, which is already on the market. An open-label, randomized, two-period, cross-over relative bioavailability study has been conducted with healthy males under fasting conditions in compliance with Good Clinical Practice (GCP) principles. A single dose of the novel tablet formulation of 600 mg cefdinir has been compared to two doses of Cefdinir 300 mg Capsules (two capsules at once) in terms of their pharmacokinetic properties. The comparison study was performed as a single-center clinical study, and blood samples of the participants were withdrawn at specified time points, before and after dosing. The plasma concentrations and pharmacokinetic properties of two cefdinir formulations were assessed from the collected samples by using a validated LC-MS/MS analytical method. The relative bioavailability of the new formulation has been shown and both products were introduced as safe.